FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040477035> ?p ?o ?g. }

• W2040477035 endingPage "B215" @default.
• W2040477035 startingPage "B209" @default.
• W2040477035 abstract "Although RSV has been a high priority for vaccine development, efforts to develop a safe and effective vaccine have yet to lead to a licensed product. Clinical and epidemiologic features of RSV disease suggest there are at least 4 distinct target populations for vaccines, the RSV naïve young infant, the RSV naïve child ≥6 months of age, pregnant women (to provide passive protection to newborns), and the elderly. These target populations raise different safety and efficacy concerns and may require different vaccination strategies. The highest priority target population is the RSV naïve child. The occurrence of serious adverse events associated with the first vaccine candidate for young children, formalin inactivated RSV (FI-RSV), has focused vaccine development for the young RSV naïve child on live virus vaccines. Enhanced disease is not a concern for persons previously primed by a live virus infection. A variety of live-attenuated viruses have been developed with none yet achieving licensure. New live-attenuated RSV vaccines are being developed and evaluated that maybe sufficiently safe and efficacious to move to licensure. A variety of subunit vaccines are being developed and evaluated primarily for adults in whom enhanced disease is not a concern. An attenuated parainfluenza virus 3 vector expressing the RSV F protein was evaluated in RSV naïve children. Most of these candidate vaccines have used the RSV F protein in various vaccine platforms including virus-like particles, nanoparticles, formulated with adjuvants, and expressed by DNA or virus vectors. The other surface glycoprotein, the G protein, has also been used in candidate vaccines. We now have tools to make and evaluate a wide range of promising vaccines. Costly clinical trials in the target population are needed to evaluate and select candidate vaccines for advancement to efficacy trials. Better data on RSV-associated mortality in developing countries, better estimates of the risk of long term sequelae such as wheezing after infection, better measures of protection in target populations, and data on the costs and benefits of vaccines for target populations are needed to support and justify funding this process. Addressing these challenges and needs should improve the efficiency and speed of achieving a safe and effective, licensed RSV vaccine." @default.
• W2040477035 created "2016-06-24" @default.
• W2040477035 creator A5021608465 @default.
• W2040477035 creator A5022497236 @default.
• W2040477035 creator A5023256503 @default.
• W2040477035 creator A5045224941 @default.
• W2040477035 creator A5086124703 @default.
• W2040477035 creator A5087452041 @default.
• W2040477035 date "2013-04-01" @default.
• W2040477035 modified "2023-10-04" @default.
• W2040477035 title "Strategic priorities for respiratory syncytial virus (RSV) vaccine development" @default.
• W2040477035 cites W1547768824 @default.
• W2040477035 cites W1894593978 @default.
• W2040477035 cites W1913350003 @default.
• W2040477035 cites W1925238017 @default.
• W2040477035 cites W1968605303 @default.
• W2040477035 cites W1975386460 @default.
• W2040477035 cites W1986189079 @default.
• W2040477035 cites W1989501142 @default.
• W2040477035 cites W1989959574 @default.
• W2040477035 cites W1994829194 @default.
• W2040477035 cites W1996443074 @default.
• W2040477035 cites W2003652041 @default.
• W2040477035 cites W2012660080 @default.
• W2040477035 cites W2016048024 @default.
• W2040477035 cites W2020583927 @default.
• W2040477035 cites W2025391611 @default.
• W2040477035 cites W2035414819 @default.
• W2040477035 cites W2043864886 @default.
• W2040477035 cites W2049928680 @default.
• W2040477035 cites W2055180355 @default.
• W2040477035 cites W2071660631 @default.
• W2040477035 cites W2074675597 @default.
• W2040477035 cites W2077290707 @default.
• W2040477035 cites W2085651049 @default.
• W2040477035 cites W2087185510 @default.
• W2040477035 cites W2089706449 @default.
• W2040477035 cites W2099904077 @default.
• W2040477035 cites W2106450636 @default.
• W2040477035 cites W2116002381 @default.
• W2040477035 cites W2120949068 @default.
• W2040477035 cites W2123817481 @default.
• W2040477035 cites W2138406799 @default.
• W2040477035 cites W2139677262 @default.
• W2040477035 cites W2144163736 @default.
• W2040477035 cites W2160551993 @default.
• W2040477035 cites W2165195150 @default.
• W2040477035 cites W2166245578 @default.
• W2040477035 cites W2328116798 @default.
• W2040477035 cites W2333994510 @default.
• W2040477035 cites W4292315834 @default.
• W2040477035 doi "https://doi.org/10.1016/j.vaccine.2012.11.106" @default.
• W2040477035 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3919153" @default.
• W2040477035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23598484" @default.
• W2040477035 hasPublicationYear "2013" @default.
• W2040477035 type Work @default.
• W2040477035 sameAs 2040477035 @default.
• W2040477035 citedByCount "197" @default.
• W2040477035 countsByYear W20404770352013 @default.
• W2040477035 countsByYear W20404770352014 @default.
• W2040477035 countsByYear W20404770352015 @default.
• W2040477035 countsByYear W20404770352016 @default.
• W2040477035 countsByYear W20404770352017 @default.
• W2040477035 countsByYear W20404770352018 @default.
• W2040477035 countsByYear W20404770352019 @default.
• W2040477035 countsByYear W20404770352020 @default.
• W2040477035 countsByYear W20404770352021 @default.
• W2040477035 countsByYear W20404770352022 @default.
• W2040477035 countsByYear W20404770352023 @default.
• W2040477035 crossrefType "journal-article" @default.
• W2040477035 hasAuthorship W2040477035A5021608465 @default.
• W2040477035 hasAuthorship W2040477035A5022497236 @default.
• W2040477035 hasAuthorship W2040477035A5023256503 @default.
• W2040477035 hasAuthorship W2040477035A5045224941 @default.
• W2040477035 hasAuthorship W2040477035A5086124703 @default.
• W2040477035 hasAuthorship W2040477035A5087452041 @default.
• W2040477035 hasBestOaLocation W20404770351 @default.
• W2040477035 hasConcept C104317684 @default.
• W2040477035 hasConcept C159047783 @default.
• W2040477035 hasConcept C159110408 @default.
• W2040477035 hasConcept C203014093 @default.
• W2040477035 hasConcept C22070199 @default.
• W2040477035 hasConcept C2522874641 @default.
• W2040477035 hasConcept C2780727368 @default.
• W2040477035 hasConcept C2780813555 @default.
• W2040477035 hasConcept C2781234862 @default.
• W2040477035 hasConcept C2781445406 @default.
• W2040477035 hasConcept C2908647359 @default.
• W2040477035 hasConcept C54602769 @default.
• W2040477035 hasConcept C55493867 @default.
• W2040477035 hasConcept C60987743 @default.
• W2040477035 hasConcept C71924100 @default.
• W2040477035 hasConcept C86803240 @default.
• W2040477035 hasConcept C99454951 @default.
• W2040477035 hasConceptScore W2040477035C104317684 @default.
• W2040477035 hasConceptScore W2040477035C159047783 @default.
• W2040477035 hasConceptScore W2040477035C159110408 @default.
• W2040477035 hasConceptScore W2040477035C203014093 @default.

• next